ModeX Therapeutics Inc, announces that the first participant has been dosed in the phase I trial (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate being developed alongside Merck, referred to as MSD outside the U.S. and Canada...
The US Food and Drug Administration (FDA) released a draft guidance in collaboration with the Office for Human Research Protections that, once finalized, will offer suggestions for incorporating tissue biopsies into clinical trials. The draft...
Adcentrx Therapeutics (Adcentrx), a biotechnology company in clinical development focused on pioneering protein conjugates for cancer and other serious diseases, announced that the first patient has been dosed in the phase 1a/b trial of ADRX-0405...
Hanx Biopharma, Inc. Ltd, a pioneering biotechnology firm focused on creating next-generation immunotherapies to tackle the challenges posed by unmet medical needs, announced the first patient dosing in Australia on December 30, 2024, for the...
The market for AI in clinical trials is fueled by the significant rate of clinical trial failures, the growing demand for predicting drug pharmacokinetics, pharmacodynamics, and toxicity management. The worldwide market for artificial intelligence...
The Clinical Trial Supplies market is driven by advanced technologies like blockchain and IoT in supply chain management. The market is projected to increase from US$2.70 Bn in 2024 to US$4.79 Bn by 2033, achieving a CAGR of 6.58% throughout the...
Lipella Pharmaceuticals Inc has reported the conclusion of dosing for the initial group in its multi-center phase 2a clinical trial for LP-310, a liposomal-tacrolimus oral rinse intended for treating oral lichen planus (OLP). In the initial group...
Marksans Pharma Limited has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg. These tablets are intended for over-the-counter (OTC) use to tre...
In 2023, international pharmaceutical firms supplied clinical trial medications to local patients valued at approximately 320.8 billion. The overall quantity of clinical trials carried out that year was 1,723, reflecting a 7.7 percent rise...
SystImmune, Inc (SystImmune), a biotechnology company in the clinical stage, declared that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC)...